Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
NCT ID: NCT02593149
Last Updated: 2019-02-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1902 participants
INTERVENTIONAL
2015-11-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
NCT02604264
Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis
NCT06024135
Assessment of a Wearable Ultrafiltration Device
NCT06832696
Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial
NCT07019610
Comparison of Dialysis Therapies on Cognitive Function
NCT00597103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
ClearGuard HD End Cap
ClearGuard HD End Cap
The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
Control
Tego® connector with the CurosTM for Tego disinfecting port protector
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ClearGuard HD End Cap
The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Davita Clinical Research
INDUSTRY
Pursuit Vascular, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven M Brunelli, MD, MSCE
Role: PRINCIPAL_INVESTIGATOR
DaVita Clinical Research / DaVita HealthCare Partners
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DaVita Clinical Research
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, Lynch LE, Killion DP. Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection. J Am Soc Nephrol. 2018 Apr;29(4):1336-1343. doi: 10.1681/ASN.2017080870. Epub 2018 Feb 22.
Related Links
Access external resources that provide additional context or updates about the study.
Pursuit Vascular website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLP-0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.